Goldman Sachs Added Genzyme (GENZ) to its Conviction Sell List
More News related to GENZ
- Morgan Joseph Reiterates a 'Buy' on Isis Pharmaceuticals (ISIS); Could Be Acquired by Potential Partners
- Piper Jaffray Maintains an 'Overweight' on ISIS Pharmaceuticals (ISIS); Price Target Cut
- Genzyme Corp. (GENZ) Announces Reports on Phase 2/3 for Advanced Phosphate Binder
- Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder
- Genzyme (GENZ) and Isis Pharma (ISIS) Announce Phase 3 Data from Mipomersen Study
More News related to Analyst Comments
- Susquehanna Maintains a 'Positive' Rating on Hewlett-Packard (HPQ); Raises PT to $58
- Credit Suisse Maintains an 'Outperform' on Newmont Mining (NEM), Raises PT
- Ford (F) Analyst Falls Asleep at the Wheel, Can't Get Ahead of the Stock
- JP Morgan Makes Positive Comments on GE: Sees Improvements in GE Capital
- Brean Murray Maintains a 'Buy' on Tech Data (TECD); Raises PT to $50
Goldman Sachs added Genzyme Corp. (Nasdaq: GENZ) to its Conviction Sell List and lowers their price target to $44, which implies downside of 10%. The firm thinks 2009-2001 consensus revenues are too high, saying Cerezyme shortage near-term could be more severe and manufacturing setbacks at Allston may impair long-term growth.
Genzyme Corporation operates as a biotechnology company worldwide.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
Analyst CommentsTrader Talk
Stocks Mentioned
-0.20Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
